Immunologic Monitoring and Cellular Products Laboratory

翻译后摘要：免疫监测和细胞产品实验室（IMCPL） 免疫监测和细胞产品实验室（IMCPL）的目标是支持 开发癌症的细胞、病毒或基因疗法，并监测对这些疗法的免疫反应 在希尔曼癌症中心（HCC）参加临床试验的患者中，IMCPL是一个独特的设施 为HCC研究人员提供一套全面的最先进的技术和分析， 各种生物疗法的临床试验和监测对这些疗法的免疫反应。IMCPL还支持 临床前开发项目，以便将来转化为临床试验。IMCPL由Theresa Whiteside博士领导， (CII)他负责监督HCC研究馆内20名全职员工的工作。服务 由CLIA/CAP认证实验室中经过培训的人员提供，具有独立的质量保证（QA） 上级要员IMCPL主要支持临床和翻译CII和CT研究计划。2019财年， IMCPL为35名HCC成员（87%的使用率）/研究方案提供了62项独立临床试验服务，所有 与HCC的使命相关，即为癌症患者提供新的免疫疗法驱动的临床试验。期间 在下一个项目期间，IMCPL将增加9个新的洁净室，从而扩大治疗性细胞的生产能力， 计划在未来增加用于治疗的细胞产品的库。它还在升级其监控 分析单细胞和外泌体分子谱的能力。

Abstract: Immunologic Monitoring and Cellular Products Laboratory (IMCPL) The goals of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) are to support the development of cellular, viral or gene therapies for cancer and monitor immunological responses to these therapies in patents enrolled in clinical trials at the Hillman Cancer Center (HCC). IMCPL is a unique facility offering a comprehensive set of state-of-the-art technologies and assays to the HCC investigators conducting clinical trials with various biotherapies and monitoring immune responses to these therapies. IMCPL also supports pre-clinical developmental projects for future translation to clinical trials. IMCPL is led by Dr. Theresa Whiteside, (CII) who oversees a staff of 20 FTE in the facility located within the HCC Research Pavilion. Services are provided by trained personnel in a CLIA/CAP certified laboratory with independent quality assurance (QA) oversight. IMCPL primarily supports the clinical and translational CII and CT research programs. In FY2019, the IMCPL serviced 62 independent clinical trials for 35 HCC members (87% of the usage)/research protocols, all relevant to the HCC mission of providing novel immunotherapy-driven clinical trials to cancer patients. During the next project period, IMCPL will add 9 new clean rooms, thus expanding therapeutic cell production capabilities and plans to increase the repertoire of cellular products for therapy in the future. It is also upgrading its monitoring capabilities to analyses of single-cell and exosome molecular profiles.